Goldline Pharmaceutical Ltd (BSE544759) — shareholding pattern, promoter holding, financials and share price
About Goldline Pharmaceutical Ltd (BSE544759)
Goldline Pharmaceutical Ltd operates in the Pharmaceuticals industry. It trades on the BSE under scrip code 544759. Its ISIN is INE1CLW01015.
Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” [1]
Listed peers in Pharmaceuticals: ANG Lifesciences India Ltd, Rajnish Wellness Ltd, Sandu Pharmaceuticals Ltd, Lasa Supergenerics Ltd, Roopa Industries Ltd, JFL Life Sciences Ltd.
Valuation & Returns
10 Jul 2026At ₹41.1 a share on 10 Jul 2026, Goldline Pharmaceutical Ltd (BSE544759) was valued at a price-to-earnings ratio of 9.58x against an industry P/E of 36.41x and a price-to-book of 1.96x on a book value of ₹21 per share. Solomo computes return on equity of 28.89% and return on capital employed of 28.35% from filed results.
- P/E
- 9.58x
- Industry P/E
- 36.41x
- P/B
- 1.96x
- EPS (TTM)
- ₹4.11
- Book value / share
- ₹21
- ROE
- 28.89%
- ROCE
- 28.35%
- ROA
- 14.27%
- Debt / equity
- 0.64x
- Dividend yield
- 0%
- EBITDA margin
- 22.28%
- 52-week range
- ₹39.7 – ₹60
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Goldline Pharmaceutical Ltd (BSE544759) reported revenue of ₹31.2 crore, net profit of ₹4.12 crore and earnings per share of ₹5.97. That compares with revenue of ₹28.01 crore and net profit of ₹2.83 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹17.31 crore and net profit ₹2.76 crore (standalone).
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue (₹ cr) | 19.73 | 23.48 | 28.01 | 31.2 |
| Net profit (₹ cr) | 0.26 | 1.81 | 2.83 | 4.12 |
| EPS (₹) | 1.3 | 7.87 | 4.1 | 5.97 |
| Measure | 1Y |
|---|---|
| Sales growth | 19.05% |
| Profit growth | 56.35% |